drug
amoxicillin
Marketedupdated 3mo agoby NeoPharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval112 co-mentions · 34 sources
- drugVOQUEZNA DUAL PAK111 co-mentions · 39 sources
- drugVOQUEZNA TRIPLE PAK111 co-mentions · 39 sources
- drugLarotid105 co-mentions · 39 sources
- drugAMOXICILLIN AND CLAVULANATE POTASSIUM105 co-mentions · 39 sources
- tagSmall Molecule57 co-mentions · 35 sources
- companySandoz Inc14 co-mentions · 7 sources
- companyAurobindo Pharma Ltd12 co-mentions · 6 sources
all catalysts(15)
approval · 13
Aug 13, 2007
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Dec 20, 2011
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Jan 30, 2012
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Oct 29, 2014
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Feb 9, 2015
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Jan 27, 2020
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Oct 23, 2023
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Apr 25, 2024
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Apr 25, 2024
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
May 1, 2024
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Jun 24, 2024
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Jan 5, 2026
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Feb 15, 2026
approval
AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approval
amoxicillin
→
Trials studying amoxicillin
- N/ACholine to Improve Malnutrition and Enhance Cognition
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase2Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
- phase1Drug Interaction Study on Linaprazan Glurate Capsules
- phase3Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
- phase4Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
- phase3Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
- phase1A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 8, 2026
115 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- May 7, 2027method-of-use (U-1304)US 8299052265d
- Dec 8, 2026formulationUS 8357394115d
- Dec 8, 2026compositionUS 8778924115d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that